Addex Therapeutics (LSE:0QNV) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

0QNV Overzicht aandelen

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland.

Over het bedrijf

0QNV fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	1/6
Dividenden	0/6

Beloningen

Risicoanalyse

Heeft minder dan 1 jaar cash runway

Negatief eigen vermogen

Aandelen zijn zeer illiquide

Heeft geen betekenisvolle marktkapitalisatie ( CHF6M )

+ 2 meer risico's

Addex Therapeutics Ltd Concurrenten

Oncimmune Holdings

AIM:ONC

UK£11.5m

Aptamer Group

AIM:APTA

UK£4.2m

Genflow Biosciences

LSE:GENF

UK£6.4m

OptiBiotix Health

AIM:OPTI

UK£12.9m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Addex Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	CHF 0.064
52 Week Hoogtepunt	CHF 0.19
52 Week Laag	CHF 0.055
Bèta	1.93
11 maand verandering	0%
3 maanden verandering	-1.08%
1 Jaar Verandering	n/a
33 jaar verandering	-95.87%
5 jaar verandering	-95.76%
Verandering sinds IPO	-96.80%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	0QNV	GB Biotechs	GB Markt
7D	0%	1.2%	1.2%
1Y	n/a	-13.6%	11.6%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe 0QNV presteerde ten opzichte van de UK Biotechs.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe 0QNV presteerde ten opzichte van de UK markt.

Prijsvolatiliteit

Is 0QNV's price volatile compared to industry and market?
0QNV volatility
0QNV Average Weekly Movement	n/a
Biotechs Industry Average Movement	8.4%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	9.2%
10% least volatile stocks in GB Market	2.6%

Stabiele aandelenkoers: De aandelenkoers van 0QNV is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van 0QNV in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2002	23	Tim Dyer	www.addextherapeutics.com

Addex Therapeutics Ltd Samenvatting

Hoe verhouden de winst en inkomsten van Addex Therapeutics zich tot de beurswaarde?
0QNV fundamentele statistieken
Marktkapitalisatie	CHF 6.19m
Inkomsten(TTM)	-CHF 10.92m
Inkomsten(TTM)	CHF 1.38m

4.5x

P/S-verhouding

-0.6x

Koers/Winstverhouding

Is 0QNV overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
0QNV resultatenrekening (TTM)
Inkomsten	CHF 1.38m
Kosten van inkomsten	CHF 6.93m
Brutowinst	-CHF 5.55m
Overige uitgaven	CHF 5.38m
Inkomsten	-CHF 10.92m

Laatst gerapporteerde inkomsten

Mar 31, 2024

Volgende inkomensdatum

Aug 12, 2024

Winst per aandeel (EPS)	-0.11
Brutomarge	-401.85%
Nettowinstmarge	-791.44%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde 0QNV op de lange termijn?

Bekijk historische prestaties en vergelijking

0QNV Overzicht aandelen

Beloningen

Risicoanalyse

Addex Therapeutics Ltd Concurrenten

AIM:ONC

UK£11.5m

AIM:APTA

UK£4.2m

LSE:GENF

UK£6.4m

AIM:OPTI

UK£12.9m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Addex Therapeutics Ltd to Report First Half, 2024 Results on Sep 16, 2024

Addex Therapeutics Ltd and Indivior PLC Selects Clinical Candidates from Gabab Positive Allosteric Modulator Research Collaboration

Addex Therapeutics Ltd Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium

Addex Therapeutics Ltd, Annual General Meeting, Jun 28, 2024

Full year 2023 earnings released: CHF0.14 loss per share (vs CHF0.46 loss in FY 2022)

Insufficient new directors

Recent updates

Addex Therapeutics Ltd to Report First Half, 2024 Results on Sep 16, 2024

Addex Therapeutics Ltd and Indivior PLC Selects Clinical Candidates from Gabab Positive Allosteric Modulator Research Collaboration

Addex Therapeutics Ltd Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium

Addex Therapeutics Ltd, Annual General Meeting, Jun 28, 2024

Full year 2023 earnings released: CHF0.14 loss per share (vs CHF0.46 loss in FY 2022)

Insufficient new directors

Addex Therapeutics Ltd to Report Fiscal Year 2023 Results on Apr 18, 2024

Addex Therapeutics Announces the Launch of Neurosterix, Company Focused on Developing Allosteric Modulators for the Treatment of Underserved Neurological Disorders

New major risk - Shareholder dilution

Insufficient new directors

Addex Therapeutics Ltd has filed a Follow-on Equity Offering in the amount of $2.15 million.

Insufficient new directors

Addex Therapeutics Ltd to Report First Half, 2024 Results on Aug 12, 2024

Addex Therapeutics' ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients

Addex Regains Nasdaq Listing Compliance

Addex Therapeutics Announces Data Published in Brain

Addex Therapeutics Ltd announced that it has received CHF 2.7 million in funding from Indivior PLC

Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder

Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Addex Therapeutics Announces ADX71149 Phase 2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Study

No longer forecast to breakeven

Addex Regains Nasdaq Listing Compliance

No longer forecast to breakeven

No longer forecast to breakeven

Addex Therapeutics Ltd to Report Fiscal Year 2022 Results on Mar 13, 2023

No longer forecast to breakeven

Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

Addex Therapeutics Ltd announced that it has received funding from Armistice Capital LLC

Addex Therapeutics Ltd announced that it expects to receive funding from Armistice Capital LLC

No longer forecast to breakeven

Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson's Disease due to Slow Recruitment Rate

Addex Therapeutics Ltd Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study

First quarter 2022 earnings released: CHF0.15 loss per share (vs CHF0.079 loss in 1Q 2021)

Forecast to breakeven in 2024

Addex Therapeutics Ltd Completes Patient Enrollment for Dipraglurant Blepharospasm Phase 2 Clinical Study

Addex Therapeutics Ltd Expands Pipeline with Selective M4 Positive Allosteric Modulator Program

Addex Therapeutics Ltd, Annual General Meeting, May 09, 2022

Addex Therapeutics Ltd, Annual General Meeting, May 09, 2022

Forecast to breakeven in 2023

Forecast to breakeven in 2023

Addex Therapeutics Ltd announced that it has received CHF 5.427937 million in funding from Armistice Capital LLC

Addex Therapeutics Ltd announced that it expects to receive CHF 5.427937 million in funding from Armistice Capital LLC

Addex Therapeutics Ltd Initiates Phase 2 Clinical Study with Dipraglurant in Blepharospasm

Addex Therapeutics Starts Phase 2 Clinical Study of ADX71149 for Epilepsy

Addex's Dipraglurant Restores Synaptic Plasticity in Models of Dystonia

First quarter 2021 earnings released: CHF0.08 loss per share (vs CHF0.16 loss in 1Q 2020)

Revenue beats expectations

Full year 2020 earnings released: CHF0.48 loss per share (vs CHF0.56 loss in FY 2019)

Addex Therapeutics Ltd to Report Q1, 2021 Results on May 03, 2021

Enamine Ltd. Extends Collaboration with Addex Therapeutics Ltd

Addex Therapeutics Announces New Treatment Option for Severe Alcohol Use Disorder

Addex Therapeutics Ltd to Report Fiscal Year 2020 Results on Mar 08, 2021

Addex ADX71149 Receives IND Approval to Start a Phase 2a Clinical Study in Epilepsy

Addex Therapeutics Ltd to Report Q3, 2020 Results on Nov 03, 2020

First half earnings released

Addex Therapeutics Ltd to Report First Half, 2020 Results on Aug 12, 2020